Literature DB >> 24415222

Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case report.

Nagashree Seetharamu1, Jonathan Melamed, George Miller, Heidrun Rotterdam, Tamas Gonda, Gerald Villanueva, Balazs Halmos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24415222     DOI： 10.1007/s12029-013-9575-6

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  19 in total

1.  ECF in gastric cancer.

Authors:  P J Ross; M E Hill; A Norman; D Cunningham
Journal:  J Clin Oncol       Date:  2000-11-15       Impact factor: 44.544

Review 2.  Esophageal cancer.

Authors:  Peter C Enzinger; Robert J Mayer
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

3.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 5.  Chemotherapy for advanced gastric cancer.

Authors:  Anna Dorothea Wagner; Susanne Unverzagt; Wilfried Grothe; Gerhard Kleber; Axel Grothey; Johannes Haerting; Wolfgang E Fleig
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

6.  A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.

Authors:  Devon Evans; Tom Miner; Paul Akerman; Robin Millis; Maureen Jean; Teresa Kennedy; Howard Safran
Journal:  Am J Clin Oncol       Date:  2007-08       Impact factor: 2.339

7.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

9.  Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.

Authors:  Arnaud D Roth; Nicola Fazio; Roger Stupp; Stephen Falk; Jürg Bernhard; Piercarlo Saletti; Dieter Köberle; Markus M Borner; Kaspar Rufibach; Rudolf Maibach; Martin Wernli; Martin Leslie; Robert Glynne-Jones; Lukas Widmer; Matthew Seymour; Filippo de Braud
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

10.  Esophageal cancer chemotherapy: recent advances.

Authors:  David H Ilson
Journal:  Gastrointest Cancer Res       Date:  2008-03
View more
  1 in total

1.  Capilliposide C Sensitizes Esophageal Squamous Carcinoma Cells to Oxaliplatin by Inducing Apoptosis Through the PI3K/Akt/mTOR Pathway.

Authors:  Zhipeng Shen; Lixia Xu; Juan Li; Ni Zhang
Journal:  Med Sci Monit       Date:  2017-05-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.